{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:34:15Z","timestamp":1784057655438,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.lfs.2021.119069","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T23:54:52Z","timestamp":1610927692000},"page":"119069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment"],"prefix":"10.1016","volume":"274","author":[{"given":"Zhongchao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119069_bb0005","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.media.2011.05.016","article-title":"Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging","volume":"15","author":"Dabbah","year":"2011","journal-title":"Med. Image Anal."},{"key":"10.1016\/j.lfs.2021.119069_bb0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1542\/peds.2012-3494","article-title":"Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents","volume":"131","author":"Copeland","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.lfs.2021.119069_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diabres.2010.12.033","article-title":"International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus","volume":"92","author":"Li","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2021.119069_bb0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2021.119069_bb0025","first-page":"29","article-title":"Management of blood glucose in type 2 diabetes mellitus","volume":"79","author":"Ripsin","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.lfs.2021.119069_bb0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2015-1137","article-title":"Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus","volume":"37","author":"Kautzky-Willer","year":"2016","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.lfs.2021.119069_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/postgradmedj-2015-133281","article-title":"Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective","volume":"92","author":"Zaccardi","year":"2016","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.lfs.2021.119069_bb0040","article-title":"Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis","volume":"10","author":"Gu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2021.119069_bb0045","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s00125-015-3712-7","article-title":"Gut microorganisms as promising targets for the management of type 2 diabetes","volume":"58","author":"Delzenne","year":"2015","journal-title":"Diabetologia."},{"key":"10.1016\/j.lfs.2021.119069_bb0050","doi-asserted-by":"crossref","first-page":"9631435","DOI":"10.1155\/2017\/9631435","article-title":"Role of the gastrointestinal tract microbiome in the pathophysiology of diabetes mellitus","volume":"2017","author":"Sohail","year":"2017","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.lfs.2021.119069_bb0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3892\/br.2016.744","article-title":"Analysis of the add-on effect of alpha-glucosidase inhibitor, acarbose in insulin therapy: a pilot study","volume":"5","author":"Li","year":"2016","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.lfs.2021.119069_bb0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3892\/etm.2015.2199","article-title":"microRNA-184 functions as tumor suppressor in renal cell carcinoma","volume":"9","author":"Su","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.lfs.2021.119069_bb0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.2040-1124.2010.00079.x","article-title":"Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus","volume":"2","author":"Uzui","year":"2011","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.lfs.2021.119069_bb0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1463-1326.2012.01593.x","article-title":"Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus","volume":"14","author":"Pan","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2021.119069_bb0075","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2165\/11206370-000000000-00000","article-title":"Vildagliptin: a review of its use in type 2 diabetes mellitus","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs."},{"key":"10.1016\/j.lfs.2021.119069_bb0080","first-page":"23","article-title":"Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus","volume":"5","author":"Kulasa","year":"2010","journal-title":"Core Evid."},{"key":"10.1016\/j.lfs.2021.119069_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00192-016-2952-5","article-title":"Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament","volume":"27","author":"Kadam","year":"2016","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.lfs.2021.119069_bb0090","first-page":"293","article-title":"Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind","volume":"8","author":"Zhang","year":"2017","journal-title":"Controlled Crossover Trial. Diabetes Ther."},{"key":"10.1016\/j.lfs.2021.119069_bb0095","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s00125-018-4647-6","article-title":"The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice","volume":"61","author":"Olivares","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.lfs.2021.119069_bb0100","doi-asserted-by":"crossref","first-page":"33251","DOI":"10.1038\/srep33251","article-title":"Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119069_bb0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2710.2012.01339.x","article-title":"Pharmacodynamic comparison of two formulations of Acarbose 100-mg tablets","volume":"37","author":"Lee","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.lfs.2021.119069_bb0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2165\/00003495-200666150-00007","article-title":"Vildagliptin","volume":"66","author":"Henness","year":"2006","journal-title":"Drugs."},{"key":"10.1016\/j.lfs.2021.119069_bb0115","article-title":"HbA1c: target value should remain 7%","volume":"154","author":"Soeters","year":"2010","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"10.1016\/j.lfs.2021.119069_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010210","article-title":"Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study","volume":"6","author":"Sharma","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.lfs.2021.119069_bb0125","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"Gaede","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.lfs.2021.119069_bb0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.soard.2012.05.005","article-title":"Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status","volume":"8","author":"Blackstone","year":"2012","journal-title":"Surg. Obes. Relat. Dis."},{"key":"10.1016\/j.lfs.2021.119069_bb0135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/1753-0407.12406","article-title":"Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy","volume":"9","author":"Wang","year":"2017","journal-title":"J. Diabetes"},{"key":"10.1016\/j.lfs.2021.119069_bb0140","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/1753-0407.12337","article-title":"Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels","volume":"8","author":"Zhang","year":"2016","journal-title":"J. Diabetes"},{"key":"10.1016\/j.lfs.2021.119069_bb0145","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.resmic.2005.03.008","article-title":"Characterization of maltose and maltotriose transport in the acarbose-producing bacterium Actinoplanes sp","volume":"156","author":"Brunkhorst","year":"2005","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.lfs.2021.119069_bb0150","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/S0007114510000243","article-title":"Beneficial effect of xylo-oligosaccharides and fructo-oligosaccharides in streptozotocin-induced diabetic rats","volume":"104","author":"Gobinath","year":"2010","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.lfs.2021.119069_bb0155","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.diabres.2013.03.011","article-title":"Vildagliptin more effectively achieves a composite endpoint of HbA(1)c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment","volume":"100","author":"Bader","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2021.119069_bb0160","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.18632\/oncotarget.7583","article-title":"Mechanosensitive caveolin-1 activation-induced PI3K\/Akt\/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis in vivo","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.lfs.2021.119069_bb0165","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/ijcp.12212","article-title":"Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin","volume":"67","author":"Karyekar","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.lfs.2021.119069_bb0170","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diabres.2011.01.022","article-title":"Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes","volume":"92","author":"Kim","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2021.119069_bb0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/jc.2008-1135","article-title":"Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes","volume":"94","author":"D\u2019Alessio","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2021.119069_bb0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/dia.2011.0278","article-title":"Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients","volume":"14","author":"Derosa","year":"2012","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.lfs.2021.119069_bb0185","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1463-1326.2011.01417.x","article-title":"Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes","volume":"13","author":"Henry","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2021.119069_bb0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.diabres.2014.05.006","article-title":"Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes","volume":"105","author":"Sjostrand","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2021.119069_bb0195","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/gutjnl-2012-302167","article-title":"Intestinal microbiota in functional bowel disorders: a Rome foundation report","volume":"62","author":"Simren","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.lfs.2021.119069_bb0200","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.aao5774","article-title":"Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes","volume":"359","author":"Zhao","year":"2018","journal-title":"Science."},{"key":"10.1016\/j.lfs.2021.119069_bb0205","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ismej.2009.112","article-title":"Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice","volume":"4","author":"Zhang","year":"2010","journal-title":"ISME J."},{"key":"10.1016\/j.lfs.2021.119069_bb0210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cell.2014.05.052","article-title":"Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences","volume":"158","author":"Cox","year":"2014","journal-title":"Cell."},{"key":"10.1016\/j.lfs.2021.119069_bb0215","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/4441009a","article-title":"Physiology: obesity and gut flora","volume":"444","author":"Bajzer","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.lfs.2021.119069_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119069_bb0225","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.lfs.2021.119069_bb0230","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature07540","article-title":"A core gut microbiome in obese and lean twins","volume":"457","author":"Turnbaugh","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.lfs.2021.119069_bb0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrmicro3089","article-title":"The gut microbiota and obesity: from correlation to causality","volume":"11","author":"Zhao","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2021.119069_bb0240","doi-asserted-by":"crossref","first-page":"109138","DOI":"10.1016\/j.biopha.2019.109138","article-title":"Research progress in the relationship between type 2 diabetes mellitus and intestinal flora","volume":"117","author":"Ma","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2021.119069_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature12198","article-title":"Gut metagenome in European women with normal, impaired and diabetic glucose control","volume":"498","author":"Karlsson","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.lfs.2021.119069_bb0250","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/db08-1637","article-title":"Butyrate improves insulin sensitivity and increases energy expenditure in mice","volume":"58","author":"Gao","year":"2009","journal-title":"Diabetes."},{"key":"10.1016\/j.lfs.2021.119069_bb0255","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1099\/ijs.0.007674-0","article-title":"Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family \u2018Porphyromonadaceae\u2019 isolated from rat faeces","volume":"59","author":"Sakamoto","year":"2009","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"10.1016\/j.lfs.2021.119069_bb0260","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jfda.2016.03.003","article-title":"Influence of gallic acid on alpha-amylase and alpha-glucosidase inhibitory properties of acarbose","volume":"24","author":"Oboh","year":"2016","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.lfs.2021.119069_bb0265","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1507\/endocrj.EJ12-0288","article-title":"Octreotide improves early dumping syndrome potentially through incretins: a case report","volume":"60","author":"Sato","year":"2013","journal-title":"Endocr. J."},{"key":"10.1016\/j.lfs.2021.119069_bb0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/VHRM.S16925","article-title":"Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies","volume":"7","author":"Schweizer","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.lfs.2021.119069_bb0275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/VHRM.S39300","article-title":"Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment","volume":"9","author":"Lukashevich","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.lfs.2021.119069_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CMED.S5114","article-title":"Saxagliptin: a selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus","volume":"4","author":"Shubrook","year":"2011","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521000540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521000540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:43:23Z","timestamp":1758401003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521000540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":56,"alternative-id":["S0024320521000540"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119069","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119069"}}